Floatz Rating
CC46/100
Confidence
Indicative
Sponsor
Biocodex
Modality
Small molecule
Development Phase
Phase 1
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
32High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07176832CT.gov Bioavailability of Stiripentol After Single Oral Dose of Capsule vs Suspension in Healthy Subjects (STILIQ) | — | Completed | — | — | — |
NCT01533506CT.gov Stiripentol in Dravet Syndrome | — | No Longer Available | — | — | — |
NCT01835314CT.gov Compassionate Use of Stiripentol in Dravet Syndrome | — | No Longer Available | — | — | — |
NCT01983722CT.gov Treatment Plan to Provide Expanded Access to Stiripentol for Patients With Dravet Syndrome | — | Approved For Marketing | — | — | — |
NCT02239276CT.gov Expanded Access Use of Stiripentol in Dravet Syndrome or Sodium Channel Mutation Epileptic Encephalopathies | — | No Longer Available | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Dravet Syndrome
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Stiripentol (this asset) | Biocodex | P1 | CC · 46 |
| Benzeneethanamine, N-Ethyl-?-Methyl-4-(Trifluoromethyl)-, Hydrochloride, (±)- | The University of Texas Health Science Center, Houston | P4 | BBB |
| Rna, (P-Thio)[2?-O-(2-Methoxyethyl)](A-G-M?U-M?U-G-G-A-G-M?C-A-A-G-A-M?U-M?U-A-M?U-M?C) | Stoke Therapeutics, Inc | P3 | BB |
| Bexicaserin | Longboard Pharmaceuticals | P3 | BB |
| gwp42003-p | Jazz Pharmaceuticals | P3 | BB |
| Clemizole | Epygenix | P3 | BB |
| Soticlestat | Takeda | P3 | B |
| Clobazam | H. Lundbeck A/S | P3 | B |
| Verapamil Slow Release | Gillette Children's Specialty Healthcare | P2 | B |
+7 more in the Dravet Syndrome cohort
Other indications for Stiripentol
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Focal Epilepsy | — | P4 | BB · 69 |
| Developmental And Epileptic Encephalopathy | — | P1 | CC · 47 |
| Epilepsy | — | P1 | CC · 42 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
- Benzeneethanamine, N-Ethyl-?-Methyl-4-(Trifluoromethyl)-, Hydrochloride, (±)-The University of Texas Health Science Center, HoustonBBB
- Rna, (P-Thio)[2?-O-(2-Methoxyethyl)](A-G-M?U-M?U-G-G-A-G-M?C-A-A-G-A-M?U-M?U-A-M?U-M?C)Stoke Therapeutics, IncBB
- BexicaserinLongboard PharmaceuticalsBB
- gwp42003-pJazz PharmaceuticalsBB
- ClemizoleEpygenixBB
Citation
Floatz Terminal. Stiripentol in Dravet Syndrome. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/stiripentol-dravet-syndrome
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →